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Background: This study aimed to evaluate the antitumor enhancing effect of bromelain 
consumption on 4T1-challenged mice treated with cisplatin. Methods: Mice challenged with 
4T1 triple-negative breast cancer cells received water, bromelain, cisplatin, or bromelain + 
cisplatin treatment for 28 days. Tumor size was measured, and lung metastasis was evaluated 
by clonogenic assay. Expression of tumor inflammatory genes of the harvested tumor was 
quantified by polymerase chain reaction array and ELISA (enzyme-linked immunosorbent 
assay). Results: All treatments significantly reduced the size of tumor and lung metastasis, 
with combination treatment showing the best effect. Also, bromelain alone and combination 
treatment showed downregulation of the expression of tumor inflammatory genes (Gremlin 
[GREM1], interleukin 1β [IL-1β], interleukin-4 [IL-4], nuclear factor κB subunit 1 [NFκB1], 
and prostaglandin-endoperoxide synthase 2 [PTGS2]), tumor nitric oxide level, and serum 
IL-1β, and IL-4 levels. On the other hand, cisplatin treatment increased the expression of 
selected inflammatory markers. Conclusion: This study suggests that bromelain treatment 
could potentiate the antitumor effect of cisplatin on triple-negative breast cancer 4T1 cells 
through modulating the tumor environmental inflammation. 
Keyword: Antitumor; Bromelain; Cisplatin; Inflammation; In vivo 
